局限期前列腺癌现代放疗模式的患者体验与治疗后悔比较
SBRT组后悔率5%,显著低于HDR组18%和IMRT组19%(P<.01)。
要点
- SBRT组治疗后悔率5%,显著低于HDR组18%和IMRT组19%(P<.01)。
- 多因素分析中HDR相对SBRT后悔风险高7.42倍,IMRT相对SBRT高11.11倍(P<.01)。
- SBRT组43%认为实际长期毒性明显低于预期,高于IMRT组20%和HDR组10%(P<.01)。
核心结论
- SBRT、IMRT与HDR三种现代放疗模式间患者体验存在显著差异,SBRT患者治疗后悔更少且实际毒性低于预期者更多。
- 表达治疗后悔的患者中多数现在希望当初选择主动监测,提示治疗前咨询至关重要。
研究设计与样本
- 研究为对2008—2014年接受SBRT、IMRT或HDR近距离治疗的局限期前列腺癌患者进行的问卷调查,随访至少1年。
- 患者中位年龄68岁,治疗后中位随访时间47个月。
主要发现
- 后悔患者中71%现在希望当初选择主动监测。
- 各模式后悔率分别为SBRT 5%、HDR 18%、IMRT 19%,差异有统计学意义(P<.01)。
- 多因素logistic回归显示HDR相对SBRT后悔风险比为7.42(P<.01),IMRT相对SBRT为11.11(P<.01)。
- 认为实际长期毒性明显低于预期者比例分别为SBRT 43%、IMRT 20%、HDR 10%(P<.01)。
临床怎么用
- 治疗前咨询应告知患者不同放疗模式间患者体验与后悔率的差异,并结合患者偏好共同决策。
- 对后悔患者应关注其可能更倾向主动监测的意愿,在随访沟通中予以回应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients' perspectives on their treatment experiences have not been compared between modern radiation modalities for localized prostate cancer. We evaluated treatment regret and patients' perceptions of their treatment experiences to better inform our understanding of a treatment's value. METHODS AND MATERIALS: Patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), or high-dose-rate (HDR) brachytherapy between 2008 and 2014 with at least 1 year of follow-up were surveyed. The questionnaire explored the decision-making experience, expectations of toxicities versus the reality, and treatment regret by means of a validated tool. RESULTS: Three hundred twenty-nine consecutive patients were surveyed, with an 86% response rate (IMRT, n=74; SBRT, n=108; HDR, n=94). The median patient age and posttreatment follow-up time were 68 years and 47 months, respectively. Eighty-two percent of patients had T1c disease with either Gleason 6 (42%) or Gleason 7 (58%) pathologic features and a median initial prostate-specific antigen of 5.8 ng/mL. Thirteen percent expressed regret with their treatment. Among patients with regret, 71% now wish they had elected for active surveillance. The incidence of regret was significantly different between treatment modalities: 5% of patients treated with SBRT expressed regret versus 18% with HDR and 19% with IMRT (P<.01). On multivariable logistic regression, patients treated with HDR versus SBRT were 7.42 times more likely to have regret, and patients treated with IMRT versus SBRT were 11.11 times more likely to have regret (P<.01 and P<.01, respectively). Significantly more patients treated with SBRT selected that their actual long-term toxicities were significantly less than originally expected, compared with IMRT and HDR patients (SBRT 43% vs IMRT 20% vs HDR 10%, P<.01). CONCLUSIONS: We found significant differences in patients' experiences between SBRT, IMRT, and HDR, with significantly less treatment regret and less toxicity than expected among SBRT patients. The majority of patients with regret would now opt for active surveillance; therefore, pretreatment counseling is essential.
引用
- Shaverdian N, Verruttipong D, Wang PC, et al. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28126301. doi:10.1016/j.ijrobp.2016.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。